Short answer
Insmed Incorporated (INSM) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Boilerplate incorporation-by-reference disclaimer, not substantive Regulation FD disclosure.
Insmed Incorporated 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate incorporation-by-reference disclaimer, not substantive Regulation FD disclosure
- No investor-actionable operating, financial, or strategic information in the provided text
Item EX-99.1 · Exhibit EX-99.2
- TPIP delivered sustained 12-month efficacy improvements, supporting advancement of the once-daily therapy into Phase 3 PALM-PAH
- 6MWD improved 55.7 meters in TPIP Continued and 54.1 meters in Placebo Crossed groups
- NT-proBNP declined approximately 60%, while 78.3% and 80.6% achieved WHO Functional Class I or II
- Approximately 65% achieved Refined Low Risk status, associated with less than 5% estimated three-year mortality risk
- No newly identified safety signals through doses up to 1,280 µg; four deaths occurred, none considered TPIP-related
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insmed Incorporated 8-K filings
Get the next INSM 8-K as it lands
Follow INSM for push alerts, or ask the research agent what this filing means.